Triazavirin API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Triazavirin API 123606-06-4?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Triazavirin. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Triazavirin
- Synonyms:
- Riamilovir , Triazavirin
- Cas Number:
- 123606-06-4
- DrugBank number:
- DB15622
- Unique Ingredient Identifier:
- F2HTG1MH2D
General Description:
Triazavirin, identified by CAS number 123606-06-4, is a notable compound with significant therapeutic applications. Triazavirin is a guanine nucleotide analog antiviral originally developed in Russia that has shown efficacy against influenza A and B, including the H5N1 strain. It appears that Triazavirin has shown promise in reducing influenza disease severity and associated complications. Given the similarities between SARS-CoV-2 and H5N1, health officials are investigating Triazavirin as an option to combat SARS-CoV-2, the coronavirus responsible for COVID-19.
Indications:
This drug is primarily indicated for: Triazavirin was developed in Russia as a potential treatment of Influenza A and B infections. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Metabolism:
Triazavirin undergoes metabolic processing primarily in: Data regarding the metabolism of triazavirin is not readily available. This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.
Absorption:
The absorption characteristics of Triazavirin are crucial for its therapeutic efficacy: In rabbits, intragastric triazavirin reaches a Cmax of 1.1±0.1mg/L, with a Tmax of 0.40±0.16h, and an AUC of 3.10±0.8mg\*h/L. In rabbits, intravenous triazavirin has an AUC of 1.2±0.3mg\*h/L. In humans, triazavirin reaches a Cmax of 4.8µg/mL, with a Tmax of 1-1.5h, and an AUC of 12.8µgµg/h\*mL. The drug's ability to rapidly penetrate into cells ensures quick onset of action.
Half-life:
The half-life of Triazavirin is an important consideration for its dosing schedule: In rabbits, intragastric triazavirin has a half life of 1.1±0.1h while intravenous triazavirin has a half life of 0.50±0.09h. The half life of triazavirin is 1-1.5h. This determines the duration of action and helps in formulating effective dosing regimens.
Protein Binding:
Triazavirin exhibits a strong affinity for binding with plasma proteins: Data regarding the protein binding of triazavirin is not readily available. This property plays a key role in the drug's pharmacokinetics and distribution within the body.
Route of Elimination:
The elimination of Triazavirin from the body primarily occurs through: Data regarding the route of elimination of triazavirin is not readily available. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.
Volume of Distribution:
Triazavirin is distributed throughout the body with a volume of distribution of: In rabbits, intragastric triazavirin has a volume of distribution of 83.5±19.2L/kg while intravenous triazavirin has a volume of distribution of 1.2±0.3L/kg. This metric indicates how extensively the drug permeates into body tissues.
Clearance:
The clearance rate of Triazavirin is a critical factor in determining its safe and effective dosage: In rabbits, intragastric triazavirin has a clearance of 37.0±11.2L/h\*kg while intravenous triazavirin has a clearance of 14.0±3.7L/h\*kg. The clearance of triazavirin is 246mL/min. It reflects the efficiency with which the drug is removed from the systemic circulation.
Mechanism of Action:
Triazavirin functions by: Triazavirin is a guanosine nucleotide analog that inhibits RNA synthesis. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Toxicity:
Categories:
Triazavirin is categorized under the following therapeutic classes: Antiviral Agents, Experimental Unapproved Treatments for COVID-19, Guanine Nucleotides. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Experimental Properties:
Further physical and chemical characteristics of Triazavirin include:
- logP: 2.038
Triazavirin is a type of Anti-infective Agents
Anti-infective agents are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of various infectious diseases. These agents play a crucial role in combating bacterial, viral, fungal, and parasitic infections. The demand for effective anti-infective APIs has grown significantly due to the increasing prevalence of drug-resistant microorganisms.
Anti-infective APIs encompass a wide range of substances, including antibiotics, antivirals, antifungals, and antiparasitics. Antibiotics are particularly important in fighting bacterial infections and are further categorized into different classes based on their mode of action and target bacteria. Antivirals are designed to inhibit viral replication and are essential in the treatment of viral infections such as influenza and HIV. Antifungals combat fungal infections, while antiparasitics are used to eliminate parasites that cause diseases like malaria and helminthiasis.
The development and production of high-quality anti-infective APIs require stringent manufacturing processes and adherence to regulatory standards. Pharmaceutical companies invest heavily in research and development to discover new and more effective anti-infective agents. Additionally, ensuring the safety, efficacy, and stability of these APIs is of utmost importance.
The global market for anti-infective APIs is driven by factors such as the rising incidence of infectious diseases, the emergence of new and drug-resistant pathogens, and the growing demand for improved healthcare infrastructure. Continuous advancements in pharmaceutical technology and the development of innovative drug delivery systems further contribute to the expansion of this market.
In conclusion, anti-infective agents are a critical category of pharmaceutical APIs that play a pivotal role in treating infectious diseases. Their effectiveness in combating various types of infections makes them essential components in the arsenal of modern medicine.
